Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Çѱ¹ÀÎÀÇ ¾Ç¼º¸²ÇÁÁ¾¿¡ °¨¿°µÇ¾î ÀÖ´Â Epstein-Bar VirusÀÇ ¾ÆÇü Subtypes of Epstein-Barr Virus in Malignant Lymphoma in Korea

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 2È£ p.338 ~ 349
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖ°æÀº/Kyung-Eun Choi Á¶ÀºÀ±/¹ÚÂù±Ý/ÀÌ¿ø±Ù/°í¿µÇý/ÃÖ°æÀº/Á¶ÀºÀ±/°í¿µÇý/Eun-Yoon Choi/Chan-Keum Park/Won-Keun Lee/Young-Hyeh Ko/Kyung-Eun Choi/Eun-Yoon Choi/Young-Hyeh Ko

Abstract

¼­·Ð
Epstein-Barr virus(EBV)´Â gamma herpes family¿¡ ¼ÓÇÏ´Â ÀÎÇü herpesvirus·Î Àü¼¼°è
ÀûÀ¸·Î ºÐÆ÷µÇ¾î ÀÖÀ¸¸ç, ¼ºÀÎÀÇ ¾à 80%¿¡¼­ 90% ÀÌ»óÀÌ ÀÌµé ¹ÙÀÌ·¯½º¿¡ °¨¿°µÇ¾î ÀÖ´Ù.
ÃʱⰨ¿°Àº ´ëºÎºÐÀÌ ¹«Áõ»óÀ¸·Î ÁÖ·Î À¯¾Æ±â¿¡ ¹ß»ýÇÏ¿© Ç÷¾×ÀÇ ¸»ÃÊ B ¸²ÇÁ±¸³»¿¡ Àẹ
°¨¿°»óÅ·ΠÁ¸ÀçÇÏ´Â °æ¿ì°¡ ÀϹÝÀûÀ̳ª, û³â±â³ª ¼ºÀα⿡ ÃÊ °¨¿°µÇ¾úÀ» ¶§´Â °¨¿°¼º ´Ü
ÇÙ±¸ÁõÀ¸·Î ¹ßº´ÇÑ´Ù. EBV´Â ±¸°­À¯¸ð¹é¹ÝÁõ, ¹öÅ°Æ® ¸²ÇÁÁ¾, ÈÄõ¼º ¸é¿ª°áÇÌÁõ¿¡ ¼Ó¹ßÇÑ
¸²ÇÁÁ¾, Àå±âÀÌ½Ä ÈÄ ¸²ÇÁ Áõ½Ä¼º Áúȯ, ºñ ÀεξÏ, ¸»ÃÊ T ¼¼Æ÷ ¸²ÇÁÁ¾ µî ¾ç¼º ¹× ¾Ç¼º Á¾
¾çÀÇ º´Àΰú °ü·ÃÀÌ ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖÀ¸¸ç, ÃÖ±Ù ¸î ³â µ¿¾È ÀÓ»óÇ¥º»¿¡¼­ÀÇ EBV
Ư¼º¿¬±¸¿¡ ´ëÇÑ °ü½ÉÀÌ ±Þ°ÝÈ÷ Áõ°¡ÇÏ°í ÀÖ´Ù. EBV´Â ÇÙ Ç׿ø¼º ´Ü¹éÁú(EBNA, EBV-
determined nuclear antigen)À» ¾ÏÈ£ÇÏ´Â À¯ÀüÀÚ ¿°±â¼­¿­ÀÇ ´Ù¾ç¼º¿¡ ±Ù°ÅÇÏ¿© EBV 1Çü°ú
EBV 2ÇüÀÇ µÎ ÇüÅ·ΠºÐ·ùµÈ´Ù. °¡Àå Å« Â÷ÀÌÁ¡À» º¸ÀÌ´Â EBNA-2´Â ´ë·« 50%ÀÇ »óµ¿¼º
ÀÌ ÀÖ°í, EBNA 3A, -3B, -3CÀº °¢°¢ 84.2, 79.7, 71.9%ÀÇ »óµ¿¼ºÀÌ ÀÖÀ¸¸ç, Àẹ±â µ¿¾È ¹Ù
ÀÌ·¯½ºÀÇ RNA °øÁ¤À» Á¶ÀýÇÏ´Â ´Ü¹éÁúÀ» ¾ÏÈ£ÇÏ°í ÀÖ´Â EBERÀ¯ÀüÀÚµµ EBV isolate °£¿¡
´Ù¾ç¼ºÀ» º¸ÀÌ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. EBNAÀ¯ÀüÀÚÀÇ Â÷ÀÌÁ¡Àº ¹ÙÀÌ·¯½ºÀÇ »ý¹°ÇÐÀû È°¼º
¿¡µµ ¿µÇâÀ» ¹ÌÃÄ EBV 1Çü ¹ÙÀÌ·¯½ºÀÇ °æ¿ì B ¸²ÇÁ±¸¸¦ ºÒ¸êÈ­ ½ÃÅ°´Âµ¥ 2Çü ¹ÙÀÌ·¯½ºº¸
´Ù ÈξÀ È¿°úÀûÀÎ °ÍÀ¸·Î º¸°íµÇ°í ÀÖ´Ù. ¶ÇÇÑ EBV 1Çü ¹ÙÀÌ·¯½º´Â Àü¼¼°èÀûÀÎ ºÐÆ÷¸¦ ³ª
Ÿ³»¸ç, ƯÈ÷ À¯·´, ¾Æ¸Þ¸®Ä«, Áß±¹ ±×¸®°í ÀϺ» µîÁö¿¡¼­ ¿ì¼¼ÇÏ°Ô ³ªÅ¸³ª°í, EBV 2Çü ¹Ù
ÀÌ·¯½º´Â Áß¾Ó¾ÆÇÁ¸®Ä«³ª ¿À½ºÆ®·¹Àϸ®¾Æ ºÏ¹æºÎÀÇ ´º±â´Ï¼¶ µîÁö¿¡¼­ ÀÚÁÖ ³ªÅ¸³ª´Â °ÍÀ¸
·Î ¾Ë·ÁÁ® ÀÖ¾î ƯÀÌÇÑ Áö¸®ÇÐÀû ºÐÆ÷¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. º» ¿¬±¸¿¡¼­´Â Çѱ¹ÀÎÀÇ ¾Ç¼º ¸²
ÇÁÁõ½Ä¼º º´º¯¿¡ °¨¿°µÈ EBVÀÇ ¾ÆÇüÀÌ Áö¸®ÇÐÀû ȤÀº Áúº´¿¡ µû¸¥ Â÷ÀÌ°¡ ÀÖ´ÂÁö¸¦ ¾Ë¾Æ
º¸°íÀÚ ¾ç¼º¸²ÇÁÁ¶Á÷ ¹× ¾Ç¼º ¸²ÇÁÁõ½Ä¼º º´º¯ÀÇ ÆĶóÇÉ Æ÷¸ÅÁ¶Á÷ 22 ¿¹¸¦ ´ë»óÀ¸·Î ÇÙ»êÁß
ÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR) ¹× Southern blot º¸ÇÕ°áÇպм®À» ÀÌ¿ëÇÏ¿© EBVÀÇ ¾ÆÇüÀ» Á¶»çÇÏ¿´
´Ù.
#ÃÊ·Ï#
Purpose : Epstein-Barr virus(EBV) exists in the human population in two genetic
forms, usually referred to as type 1 and type 2 which have been defined on the basis of
sequence divergence in the EBNA-2 and EBNA-3 family genes. In this study, we were
intended to investigate whether the subtypes of EBV in malignant lymphoma in Korea
were associated with specific disease entities and geographical distribution.
Materials and Methods : Biopsy samples obtained from 18 Korean patients with
malignant lymphoma including Hodgkin's disease(3 cases), B cell lymphoma(1 case), and
NK/T cell lymphoma(14 cases) were analyzed to determine the subtype of EBV infected
therein. DNA was extracted from formalin-fixed, paraffin-embeded tissues by ordinary
method and specific viral sequences were sought using the polymerase chain
reaction(PCR) and Southern blot hybridization assay. Oligonucleotide primers used for
examination of EBV strain type were derived from the EBNA-3B and EBNA-3C coding
regions. As a control, four cases of reactive hyperplasia were analyzed.
Results : The two of four reactive hyperplasia cases were associated with type 1 and
the rest of two cases with both types. Among the 18 cases with malignant lymphoma,
thirteen cases(72%) had type 1, one(6%) had type 2, and four(22%) had dual infections
with both types. In case of NK/T cell lymphoma(14 cases) occupying 78% of 18 biopsy
samples, 86%(12 cases) were associated with type 1,7%(1 case) with type 2, and 7% (1
case) with both types. In case of Hodgkin's disease, all of three cases had both types.
B cell lymphoma taking only one case of twenty two cases was determined as type 1.
Conclusion : These observations indicated that type 1 EBV was predominant in
Korean patients with malignant lymphoma, especially NK/T cell lymphoma and showed
high frequency of dual viral infections(22%) in Hodgkin's disease as well as in reactive
hyperplasia.

Å°¿öµå

Epstein-Barr virus; Subtype; Genotype; Malignant lymphoma;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS